Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
=== Acting === Director Lal Jose noticed Kallingal on a magazine cover and approached her for a goat herder role in the Tamil film Mazhai Varappoguthu. The project did not go ahead, but director Shyamaprasad subsequently cast her in the lead female role of Varsha in Ritu (2009), which marked her acting debut. In 2009 she also appeared in the anthology film Kerala Cafe, in the segment Mrityunjayam, and in Neelathaamara directed by Lal Jose. In 2012, Kallingal was cast opposite Fahadh Faasil in 22 Female Kottayam, directed by Aashiq Abu, playing a nurse and rape survivor seeking justice. The film performed well commercially and won Kallingal the Kerala State Film Award for Best Actress and the Filmfare Award for Best Actress – Malayalam. The film also drew praise from critics; Sify wrote that Kallingal "poured her heart into her character" and delivered "a spectacular performance". In 2013, she hosted the Mazhavil Manorama reality show Midukki, following which the Kerala Film Chamber imposed a temporary ban on her for disregarding a recent notice by the chamber; the ban was subsequently revoked. That same year she played a housewife in August Club. Paresh C. Palicha of Rediff.com noted that Kallingal portrayed a character "who has learnt to stifle her feelings and finding other ways to give them an outlet". In 2015, she appeared alongside Manju Warrier in Rani Padmini, playing a disruptive North Indian woman on a road trip from Kerala to Shimla. The film was a commercial success and critic Deepa Soman described her performance as a "knockout".
=== Reference material === Graphene's properties suggest it as a reference material for characterizing electroconductive and transparent materials. One layer of graphene absorbs 2.3% of red light. This property was used to define the conductivity of transparency that combines sheet resistance and transparency. This parameter was used to compare materials without the use of two independent parameters.
Consumers purchase the illusion that every commodity or product is tailored to the individual's personal preference by incorporating subtle modifications or inexpensive "add-ons" to keep the consumer returning for new purchases and, therefore, more revenue for the corporation system. Adorno conceptualized this phenomenon as pseudo-individualisation and the always-the-same. Adorno's analysis allowed for a critique of mass culture from the left that balanced the critique of popular culture from the right. From both perspectives—left and right—the nature of cultural production was felt to be at the root of social and moral problems resulting from the consumption of culture. However, while the critique from the right emphasized moral degeneracy ascribed to sexual and racial influences within popular culture, Adorno located the problem, not with the content, but with the objective realities of the production of mass culture and its effects, for instance, as a form of reverse psychology. Thinkers influenced by Adorno believe that today's society has evolved in a direction foreseen by him, especially in regard to the past (Auschwitz), morals, or the Culture Industry. The latter has become a particularly productive, yet highly contested, term in cultural studies. Many of Adorno's reflections on aesthetics and music have only just begun to be debated. A collection of essays on the subject, many of which had not previously been translated into English, has only recently been collected and published as Essays on Music.
Sources: en.wikipedia.org
The tarsi (sing.: tarsus) or tarsal plates are two comparatively thick, elongated plates of dense connective tissue, about 10 mm (0.39 in) in vertical dimension for the upper eyelid and 5 mm for the lower eyelid; one is found in each eyelid, and contributes to its form and support. They are located directly above the lid margins. The tarsus has a lower and upper part making up the palpebrae.
=== Degradation === Histidine can be metabolized into glutamate, which is readily metabolized into AKG (alpha-ketoglutarate), making histidine one of the amino acids whose metabolites can become citric acid cycle intermediates. The process requires several steps. In prokaryotes, histidine first undergoes deamination, the removal of its amino group by the emzyme histidase. This step produces ammonia and urocanic acid (urocanate). The enzyme urocanase then converts urocanic acid into imidazolonepropionate (4-imidazolone-5-propionate). The enzyme imidazolonepropionase then converts imidazolonepropionate into formiminoglutamate (FIGLU). The enzyme formimidoyltransferase cyclodeaminase removes the formimino group (which is transferred to tetrahydrofolate), leaving behind a glutamate molecule. Glutamate can then be deaminated by glutamate dehydrogenase or transaminated to form α-ketoglutarate.
=== Bibliography === Wiseman A (1993). "Designer enzyme and cell applications in industry and in environmental monitoring". J Chem Technol Biotechnol. 56 (1): 3–13. Bibcode:1993JCTB...56....3W. doi:10.1002/jctb.280560103. PMID 7763363. Diekmann S, Weston J, Anders E, et al. (April 2002). "Metal-mediated reactions modeled after nature". J. Biotechnol. 90 (2): 73–94. doi:10.1016/s1389-0352(01)00067-8. PMID 12069195.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.